Pharmaceutical regulatory consulting for drug developers and CROs: IND CMC, method validation, NDA strategy, and FDA ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...
FDA draft guidance backs alternatives to animal testing in early drug development, outlining validation for new approach ...
This is the latest in a series of steps the agency has taken over the past two years to reduce reliance on animal testing. In ...
Industry groups and drugmakers want the US Food and Drug Administration (FDA) to explicitly clarify that Bayesian statistical methods can be used for products beyond those intended for children and ...
Non-animal testing methods could save drugmakers time and money, officials say ...
Federal regulators in the United States are pushing harder than ever to reduce and eventually replace animal testing in drug and chemical safety assessments. The FDA has released draft guidance ...